Microfilament-targeting agents typically work by interfering with the polymerization and depolymerization of actin filaments. Agents such as cytochalasins and latrunculins bind to actin monomers, preventing their incorporation into filaments, whereas others like jasplakinolide stabilize actin filaments, inhibiting their turnover. These disruptions can result in the inhibition of cell division, induction of apoptosis, and reduced metastatic potential, providing a promising strategy for cancer treatment.
